Skip to main content
Log in

Generalised Anxiety Disorder in Elderly Patients

Epidemiology, Diagnosis and Treatment Options

  • Therapy In Practice
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Generalised anxiety disorder (GAD) is characterised by at least 6 months of excessive uncontrollable worry accompanied by symptoms of motor tension and vigilance and scanning. As with other anxiety disorders, GAD is less prevalent in older adults than younger adults. GAD has a high level of comorbidity with other psychiatric disorders and this has a bearing on estimates of its prevalence. GAD that is comorbid with another psychiatric disorder has a period prevalence of approximately 4% in community-dwelling older people. On the other hand, ‘pure’ GAD is less common, with a period prevalence of approximately 1%. Pure GAD in late life is a fairly even mix of chronic cases that began earlier in life and cases starting for the first time in later life.

The most frequent and consistent finding regarding late-life generalised anxiety is its high level of comorbidity with major depression. There are few longitudinal data pertaining to the temporal association of generalised anxiety and major depression in late life, but the data that do exist suggest that the anxiety is frequently symptomatic of the depression. If generalised anxiety occurs exclusively during episodes of major depression, a separate diagnosis of GAD is not warranted.

Cognitive behaviour therapy (CBT) is the most frequently studied psychological treatment for GAD. Although CBT is more effective than a wait-list control condition, it is not more effective than nondirective therapies in late-life GAD. Furthermore, a standard course of CBT appears to be less efficacious for GAD in older adults than younger adults. Further research is needed to develop more efficacious and specific forms of psychotherapy for late-life GAD.

The three classes of medications that are most commonly used for GAD are: (i) antidepressants; (ii) benzodiazepines; and (iii) buspirone. Antidepressant medication is the pharmacological treatment of choice for most older adults with generalised anxiety. When generalised anxiety is secondary to an episode of major depression, the selection of an antidepressant is guided by the same principles that apply to treatment of nonanxious depression. Antidepressant medication is also effective for GAD in the absence of an episode of major depression. In this situation, citalopram and venlafaxine have been found to be efficacious in older people. Data from studies of mixed-aged patients suggest that escitalopram, paroxetine and trazodone may also be beneficial in late-life GAD. Despite their widespread use in older persons with anxiety, benzodiazepines have a limited role in the treatment of GAD in the elderly. If a benzodiazepine is initiated, pharmacokinetic considerations favour the use of either lorazepam or oxazepam. Buspirone also has a more limited role than antidepressants in the treatment of late-life GAD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III

Similar content being viewed by others

References

  1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed. Washington, DC: American Psychiatric Association, 1980

    Google Scholar 

  2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd rev. ed. Washington, DC: American Psychiatric Association, 1987

    Google Scholar 

  3. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994

    Google Scholar 

  4. Brown TA. The nature of generalized anxiety disorder and pathological worry: current evidence and conceptual models. Can J Psychiatry 1997; 42: 817–25

    PubMed  CAS  Google Scholar 

  5. Abel JL, Borkovec TD. Generalizability of DSM-III-R generalized anxiety disorders to proposed DSM-IV criteria and cross-validation of proposed changes. J Anxiety Disord 1995; 9: 303–15

    Article  Google Scholar 

  6. Wittchen HU, Zhao S, Kessler RC, et al. DSM-III-R generalized anxiety disorder in the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51: 355–64

    Article  PubMed  CAS  Google Scholar 

  7. Hunt C, Issakidis C, Andrews G. DSM-IV generalized anxiety disorder in the Australian National Survey of Mental Health and Well-Being. Psychol Med 2002; 32: 649–59

    Article  PubMed  CAS  Google Scholar 

  8. Flint AJ. Epidemiology and comorbidity of anxiety disorders in the elderly. Am J Psychiatry 1994; 151: 640–9

    PubMed  CAS  Google Scholar 

  9. Copeland JRM, Gurland BJ, Dewey ME, et al. Is there more dementia, depression and neurosis in New York? A comparative study of the elderly in New York and London using the computer diagnosis AGECAT. Br J Psychiatry 1987; 151: 466–73

    Article  PubMed  CAS  Google Scholar 

  10. Copeland JRM, Dewey ME, Wood N, et al. Range of mental illness among the elderly in the community: prevalence in Liverpool using the GMS-AGECAT package. Br J Psychiatry 1987; 150: 815–23

    Article  PubMed  CAS  Google Scholar 

  11. Blazer D, George LK, Hughes D. Generalised anxiety disorder. In: Robins LN, Regier DA, editors. Psychiatric disorders in America: the Epidemiological Catchment Area Study. New York: The Free Press, 1991: 180–203

    Google Scholar 

  12. Larkin BA, Copeland JRM, Dewey ME, et al. The natural history of neurotic disorder in an elderly urban population: findings from the Liverpool longitudinal study of continuing health in the community. Br J Psychiatry 1992; 160: 681–6

    Article  PubMed  CAS  Google Scholar 

  13. Kirby M, Bruce I, Radic A, et al. Mental disorders among the community-dwelling elderly in Dublin. Br J Psychiatry 1997; 171: 369–72

    Article  PubMed  CAS  Google Scholar 

  14. Lindesay J, Briggs K, Murphy E. The Guy’s/Age Concern Survey: prevalence rates of cognitive impairment, depression and anxiety in an urban elderly community. Br J Psychiatry 1989; 155: 317–29

    PubMed  CAS  Google Scholar 

  15. Manela M, Katona C, Livingston G. How common are the anxiety disorders in old age? Int J Geriatr Psychiatry 1996; 11: 65–70

    Article  Google Scholar 

  16. Beekman ATF, Bremmer MA, Deeg DJH, et al. Anxiety disorders in later life: a report from the longitudinal aging study Amsterdam. Int J Geriatr Psychiatry 1998; 13: 717–26

    Article  PubMed  CAS  Google Scholar 

  17. Schoevers RA, Beekman ATF, Deeg DJH, et al. Comorbidity and risk-patterns of depression, generalised anxiety disorder and mixed anxiety-depression in later life: results from the AMSTEL study. Int J Geriatr Psychiatry 2003; 18: 944–1001

    Article  Google Scholar 

  18. Uhlenhuth EH, Balter MB, Mellinger GD, et al. Symptom checklist syndromes in the general population: correlations with psychotherapeutic drug use. Arch Gen Psychiatry 1983; 40: 1167–73

    Article  PubMed  CAS  Google Scholar 

  19. Blazer D, George LK, Hughes D. The epidemiology of anxiety disorders: an age comparison. In: Salzman C, Lebowitz BD, editors. Anxiety in the elderly: treatment and research. New York: Springer Publishing, 1991: 17–30

    Google Scholar 

  20. van Balkom AJLM, Beekman AFT, de Beurs E, et al. Comorbidity of the anxiety disorders in a community-based older population in the Netherlands. Acta Psychiatr Scand 2000; 101: 37–45

    Article  PubMed  Google Scholar 

  21. Aström M. Generalized anxiety disorder in stroke patients: a 3-year longitudinal study. Stroke 1996; 27: 270–5

    Article  PubMed  Google Scholar 

  22. Castillo CS, Schultz SK, Robinson RG. Clinical correlates of early-onset and late-onset poststroke generalized anxiety. Am J Psychiatry 1995; 152: 1174–9

    PubMed  CAS  Google Scholar 

  23. Parmelee PA, Katz IR, Lawton MP. Anxiety and its association with depression among institutionalized elderly. Am J Geriatr Psychiatry 1993; 1: 46–58

    Article  Google Scholar 

  24. Livingston G, Watkin V, Milne B, et al. The natural history of depression and the anxiety disorders in older people: the Islington community study. J Affect Disord 1997; 46: 255–62

    Article  PubMed  CAS  Google Scholar 

  25. Kessler RC, DuPont RL, Berglund P, et al. Impairment in pure and comorbid generalized anxiety disorder and major depression at 12 months in two national surveys. Am J Psychiatry 1999; 156: 1915–23

    PubMed  CAS  Google Scholar 

  26. Bruce SE, Machan JT, Dyck I, et al. Infrequency of ‘pure’ GAD: impact of psychiatric comorbidity on clinical course. Depress Anxiety 2001; 14: 219–25

    Article  PubMed  CAS  Google Scholar 

  27. Flint AJ, Rifat SL. Anxious depression in elderly patients: response to antidepressant treatment. Am J Geriatr Psychiatry 1997; 5: 107–15

    PubMed  CAS  Google Scholar 

  28. Flint AJ, Rifat SL. Two-year outcome of elderly patients with anxious depression. Psychiatry Res 1997; 66: 23–31

    Article  PubMed  CAS  Google Scholar 

  29. Meyers BS, Gabriele M, Kakuma T, et al. Anxiety and depression as predictors of recurrence in geriatric depression: a preliminary report. Am J Geriatr Psychiatry 1996; 4: 252–7

    Article  Google Scholar 

  30. Szanto K, Mulsant BH, Houck PR, et al. Treatment outcome in suicidal vs non-suicidal elderly patients. Am J Geriatr Psychiatry 2001; 9: 261–8

    PubMed  CAS  Google Scholar 

  31. Shimoda K, Robinson RG. Effect of anxiety disorder on impairment and recovery from stroke. J Neuropsychiatry Clin Neurosci 1998; 10: 34–40

    PubMed  CAS  Google Scholar 

  32. Forsell Y, Winblad B. Anxiety disorders in non-demented and demented elderly patients: prevalence and correlates. J Neurol Neurosurg Psychiatry 1997; 62: 294–5

    Article  PubMed  CAS  Google Scholar 

  33. Skoog I. The prevalence of psychotic, depressive and anxiety syndromes in demented and non-demented 85-year-olds. Int J Geriatr Psychiatry 1993; 8: 247–53

    Article  Google Scholar 

  34. Ballard CG, Mohan RNC, Patel A, et al. Anxiety disorder in dementia. Ir J Psychol Med 1994; 11(3): 108–9

    Google Scholar 

  35. Ballard C, Boyle A, Bowler C, et al. Anxiety disorders in dementia sufferers. Int J Geriatr Psychiatry 1996; 11: 987–90

    Article  Google Scholar 

  36. Orrell M, Bebbington P. Psychosocial stress and anxiety in senile dementia. J Affect Disord 1996; 39: 165–73

    Article  PubMed  CAS  Google Scholar 

  37. Teri L, Ferretti LE, Gibbons LE, et al. Anxiety in Alzheimer’s disease: prevalence and comorbidity. J Gerontol 1999; 54A: M348–52

    Google Scholar 

  38. Lindesay J. The Guy’s/Age Concern Survey: physical health and psychiatric disorder in an urban elderly community. Int J Geriatr Psychiatry 1990; 5: 171–8

    Article  Google Scholar 

  39. House A, Dennis M, Mogridge L, et al. Mood disorders in the year after first stroke. Br J Psychiatry 1991; 158: 83–92

    Article  PubMed  CAS  Google Scholar 

  40. Burvill PW, Johnson GA, Jamrozik KD, et al. Anxiety disorders after stroke: results from the Perth Community Stroke Study. Br J Psychiatry 1995; 166: 328–32

    Article  PubMed  CAS  Google Scholar 

  41. Neal RM, Baldwin RC. Screening for anxiety and depression in elderly medical outpatients. Age Ageing 1994; 23: 461–4

    Article  PubMed  CAS  Google Scholar 

  42. Morris PLP, Robinson RG, Raphael B. Prevalence and course of depressive disorders in hospitalized stroke patients. Int J Psychiatry Med 1990; 20: 349–64

    Article  PubMed  CAS  Google Scholar 

  43. Stein MB, Heuser IJ, Juncos JL, et al. Anxiety disorders in patients with Parkinson’s disease. Am J Psychiatry 1990; 147: 217–20

    PubMed  CAS  Google Scholar 

  44. Menza MA, Robertson-Hoffman DE, Bonapace AS. Parkinson’s disease and anxiety: comorbidity with depression. Biol Psychiatry 1993; 34: 465–70

    Article  PubMed  CAS  Google Scholar 

  45. Lauterbach EC, Duvoisin RC. Anxiety disorders in familial Parkinsonism [letter]. Am J Psychiatry 1991; 148: 274

    PubMed  CAS  Google Scholar 

  46. Yellowlees PM, Alpers JH, Bowden JJ, et al. Psychiatric morbidity in patients with chronic airflow obstruction. Med J Aust 1987; 146: 305–7

    PubMed  CAS  Google Scholar 

  47. Lyness JM, Conwell Y, King DA, et al. Ruminative thinking in older inpatients with major depression. J Affect Disord 1997; 46: 273–7

    Article  PubMed  CAS  Google Scholar 

  48. Wetherell JL, Le Roux H, Gatz M. DSM-IV criteria for generalized anxiety disorder in older adults: distinguishing the worried from the well. Psychol Aging 2003; 18: 622–7

    Article  PubMed  Google Scholar 

  49. Wittchen H-U, Kessler RC, Beesdo K, et al. Generalized anxiety and depression in primary care: prevalence, recognition, and management. J Clin Psychiatry 2002; 63Suppl. 8: 24–34

    PubMed  Google Scholar 

  50. Judd LL, Kessler RC, Paulus MP, et al. Comorbidity as a fundamental feature of generalized anxiety disorders: results from the National Comorbidity Study (NCS). Acta Psychiatr Scand 1998; 98Suppl. 393: 6–11

    Article  Google Scholar 

  51. Kjernisted K. Generalized anxiety disorder: a diagnostic dilemma. Can J Diag 2001 Nov, 4–9

    Google Scholar 

  52. Antony MM, Swinson RP. Anxiety disorders and their treatment: a critical review of the evidence-based literature. Ottawa: Health Canada, 1996

    Google Scholar 

  53. Arntz A. Cognitive therapy versus applied relaxation as treatment of generalized anxiety disorder. Behav Res Ther 2003; 41: 633–46

    Article  PubMed  CAS  Google Scholar 

  54. Durham RC, Chambers JA, MacDonald RR, et al. Does cognitive-behavioral therapy influence the long-term outcome of generalized anxiety disorder? An 8–14 year follow-up of two clinical trials. Psychol Med 2003; 33: 499–509

    Article  PubMed  CAS  Google Scholar 

  55. Stanley MA, Beck JG, Novy DM, et al. Cognitive-behavioral treatment of late-life generalized anxiety disorder. J Consult Clin Psychol 2003; 71: 309–19

    Article  PubMed  Google Scholar 

  56. Wetherell JL, Gatz M, Craske MG. Treatment of generalized anxiety disorder in older adults. J Consult Clin Psychol 2003; 71: 31–40

    Article  PubMed  Google Scholar 

  57. Mohlman J, Gorenstein EE, Kleber M, et al. Standard and enhanced cognitive-behavior therapy for late-life generalized anxiety disorder. Am J Geriatr Psychiatry 2003; 11: 24–32

    PubMed  Google Scholar 

  58. Stanley MA, Beck JG, Glassco JD. Generalized anxiety in older adults: treatment with cognitive-behavioural and supportive approaches. Behav Ther 1997; 27: 565–81

    Article  Google Scholar 

  59. Dugas MJ, Ladouceur R, Leger E, et al. Group cognitive-behavioral therapy for generalized anxiety disorder: treatment outcome and long-term follow-up. J Consult Clin Psychol 2003; 71: 821–5

    Article  PubMed  Google Scholar 

  60. Enkelmann R. Alprazolam versus buspirone in the treatment of outpatients with generalized anxiety disorder. Psychopharmacology 1991; 105: 428–32

    Article  PubMed  CAS  Google Scholar 

  61. Fontaine R, Mercier P, Beaudry P, et al. Bromazepam and lorazepam in generalized anxiety: a placebo-controlled study with measurement of drug plasma concentrations. Acta Psychiatr Scand 1986; 74: 451–8

    Article  PubMed  CAS  Google Scholar 

  62. Pecknold JC, Matas M, Howarth BG, et al. Evaluation of buspirone as an antianxiety agent: buspirone and diazepam versus placebo. Can J Psychiatry 1989; 34: 766–71

    PubMed  CAS  Google Scholar 

  63. Casacchia M, Bolino F, Ecari U. Etizolam in the treatment of generalized anxiety disorder: a double-blind study versus placebo. Curr Med Res Opin 1990; 12: 215–23

    Article  PubMed  CAS  Google Scholar 

  64. Cutler NR, Sramek JJ, Wardle TS, et al. The safety and efficacy of ipsapirone vs lorazepam in outpatients with generalized anxiety disorder: single site findings from a multicenter trial. Psychopharmacol Bull 1993; 29: 303–8

    PubMed  CAS  Google Scholar 

  65. Lenze EJ, Shear MK, Mulsant BH, et al. Treatment of geriatric anxiety disorders: results from a placebo-controlled study of citalopram [abstract]. 3rd Annual Meeting. International College of Geriatric Psychoneuropharmacology; 2003 Dec 12–14; San Juan, 48

  66. Davidson JRT, Bose A, Korotzer A, et al. Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study. Depress Anxiety 2004; 19: 234–40

    Article  PubMed  CAS  Google Scholar 

  67. Rickels K, Downing R, Schweizer E, et al. Antidepressants for the treatment of generalized anxiety disorder: a placebo-controlled comparison of imipramine, trazodone, and diazepam. Arch Gen Psychiatry 1993; 50: 884–95

    Article  PubMed  CAS  Google Scholar 

  68. Pollack MH, Zaninelli R, Goddard A, et al. Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry 2001; 62: 350–7

    Article  PubMed  CAS  Google Scholar 

  69. Rickels K, Zaninelli R, McCafferty J, et al. Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study. Am J Psychiatry 2003; 160: 749–56

    Article  PubMed  Google Scholar 

  70. Katz IR, Reynolds CF, Alexopoulos GS, et al. Venlafaxine ER as a treatment for generalized anxiety disorder in older adults: pooled analysis of five randomized placebo-controlled clinical trials. J Am Geriatr Soc 2002; 50: 18–25

    Article  PubMed  Google Scholar 

  71. Mendels J, Krajewski TF, Huffer V, et al. Effective short-term treatment of generalized anxiety disorder with trifluoperazine. J Clin Psychiatry 1986; 47: 170–4

    PubMed  CAS  Google Scholar 

  72. Feltner DE, Crockatt JG, Dubovsky SJ, et al. A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol 2003; 23: 240–9

    PubMed  CAS  Google Scholar 

  73. Lader M, Scotto J-C. A multicentre double-blind comparison of hydroxyzine, buspirone and placebo in patients with generalized anxiety disorder. Psychopharmacology 1998; 139: 402–6

    Article  PubMed  CAS  Google Scholar 

  74. Moller H-J, Volz H-P, Reimann IW, et al. Opipramol for the treatment of generalized anxiety disorder: a placebo-controlled trial including an alprazolam-treated group. J Clin Psychopharmacol 2001; 21: 59–65

    Article  PubMed  CAS  Google Scholar 

  75. Bohm C, Robinson DS, Gammans RE, et al. Buspirone therapy in anxious elderly patients: a controlled clinical trial. J Clin Psychopharmacol 1990; 10: 47S–51S

    Article  PubMed  CAS  Google Scholar 

  76. Koepke HH, Gold RL, Linden ME, et al. Multicenter controlled study of oxazepam in anxious elderly outpatients. Psychosomatics 1982; 23: 641–5

    PubMed  CAS  Google Scholar 

  77. Birkenhager TK, Moleman P, Nolen WA. Benzodiazepines for depression? A review of the literature. Int Clin Psychopharmacol 1995; 10: 181–95

    Article  PubMed  CAS  Google Scholar 

  78. American Psychiatric Association. Benzodiazepine dependence, toxicity and abuse. Washington, DC: American Psychiatric Association, 1990

    Google Scholar 

  79. Rickels K, Schweizer E, Csanalosi I, et al. Long-term treatment of anxiety and risk of withdrawal: prospective comparison of clorazepate and buspirone. Arch Gen Psychiatry 1988; 45: 444–50

    Article  PubMed  CAS  Google Scholar 

  80. Schweizer E, Rickels K, Lucki I. Resistance to the anti-anxiety effect of buspirone in patients with a history of benzodiazepine use. N Engl J Med 1986; 314: 719–20

    Article  PubMed  CAS  Google Scholar 

  81. DeMartinis N, Rynn M, Rickels K, et al. Prior benzodiazepine use and buspirone response in the treatment of generalized anxiety disorder. J Clin Psychiatry 2000; 61: 91–4

    Article  PubMed  CAS  Google Scholar 

  82. Steinberg JR. Anxiety in elderly patients: a comparison of azapirones and benzodiazepines. Drugs Aging 1994; 5: 335–45

    Article  PubMed  CAS  Google Scholar 

  83. Schweizer E, Rickels K. Failure of buspirone to manage benzodiazepine withdrawal. Am J Psychiatry 1986; 143: 1590–2

    PubMed  CAS  Google Scholar 

  84. Flint AJ. Choosing appropriate antidepressant therapy in the elderly: a risk-benefit assessment of available agents. Drugs Aging 1998; 13: 269–80

    Article  PubMed  CAS  Google Scholar 

  85. Flint AJ, Rifat SL. Effect of demographic and clinical variables on time to antidepressant response in geriatric depression. Depress Anxiety 1997; 5: 103–7

    Article  PubMed  CAS  Google Scholar 

  86. Burke WJ. Escitalopram. Expert Opin Investig Drugs 2002; 11: 1477–86

    Article  PubMed  CAS  Google Scholar 

  87. Yonkers KA, Massion AO, Warshaw MG, et al. Phenomenology and course of generalised anxiety disorder. Br J Psychiatry 1996; 168: 308–13

    Article  PubMed  CAS  Google Scholar 

  88. Keller MB, Boland RJ. Implications of failing to achieve successful long-term maintenance treatment of recurrent unipolar major depression. Biol Psychiatry 1998; 44: 348–60

    Article  PubMed  CAS  Google Scholar 

  89. Flint AJ, Rifat SL. Recurrence of first-episode geriatric depression after discontinuation of maintenance antidepressants. Am J Psychiatry 1999; 156: 943–5

    PubMed  CAS  Google Scholar 

  90. Kirby M, Denihan A, Brace I, et al. Influence of symptoms of anxiety on treatment of depression in later life in primary care: questionnaire survey. BMJ 1999; 318: 579–80

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

Dr Flint receives salary from Toronto General Hospital, the Research Institute of Toronto Rehabilitation Institute and the University of Toronto.

The author has no conflicts of interest that are directly relevant to the content of this review.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Alastair J. Flint.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Flint, A.J. Generalised Anxiety Disorder in Elderly Patients. Drugs Aging 22, 101–114 (2005). https://doi.org/10.2165/00002512-200522020-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-200522020-00002

Keywords

Navigation